T
he White House is being urged to sidestep patents on a high-priced opioid overdose antidote as one way to stem the rising cost of combating the opioid crisis.
In a letter sent last Thursday, an advocacy group argues the White House should use a little-known federal law that would permit the government to take title to patents on Evzio. This is a decades-old version of naloxone, which is widely used to reverse the effect of opioid and heroin overdoses.
Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
